

# Total Synthesis of (+)-Dodoneine

Aurélia Dittoo, Véronique Bellosta, Janine Cossy\*

Laboratoire de Chimie Organique, ESPCI ParisTech, CNRS, 10 rue Vauquelin, 75231 Paris Cedex 05, France  
Fax +33(1)40794660; E-mail: janine.cossy@espci.fr


Received 12 June 2008

**Abstract:** An eight-step synthesis of (+)-dodoneine was achieved from methyl 3-(4-hydroxyphenyl)propionate.

**Key words:** total synthesis, dodoneine, allyltitanation, cross-metathesis, 1,4-addition

Recently, a new dihydropyranone, (+)-dodoneine, was isolated from *Tapinanthus dodoneifolius* which was collected on a sheanut tree in Loumbila (West Africa).<sup>1</sup> The structure of (+)-dodoneine was established through careful NMR and HRMS (ESI) studies. The relative configuration was determined by chemical transformations and NMR studies, and the absolute configuration by X-ray crystallographic analysis of dodoneine derivative **A**. (+)-Dodoneine was identified as a *para*-substituted phenolic ring bearing an alcohol *syn* to the hydroxyl group involved in a substituted 5,6-dihydropyran-2-one moiety<sup>1</sup> (Figure 1). Biological assays of (+)-dodoneine revealed a potent relaxing effect on precontracted rat aortic rings ( $IC_{50} = 81.4 \pm 0.9 \mu M$ ).

Herein, we would like to report a short and efficient synthesis of (+)-dodoneine. The synthesis was envisioned to begin with the commercially available methyl ester **1**. The construction of the lactone would be elaborated by using a lactonization of the unsaturated hydroxy ester **B**. An enantioselective allyltitanation and an intramolecular diastereoselective 1,4-addition of a hemiacetal of type **C** would install the two stereogenic centers (Scheme 1).



Scheme 1

The synthesis of (+)-dodoneine started with the commercially available ester **1**. After protection of the phenol (TBSCl, imidazole,  $CH_2Cl_2$ , 0 °C to r.t., 12 h, 98% yield) followed by a DIBAL-H reduction (toluene, –78 °C, 1 h, 90% yield), the desired aldehyde **2** was obtained. This aldehyde was treated directly with the highly face-selective allyltitanium complex (*S,S*)-Ti-I<sup>2</sup> ( $Et_2O$ , –78 °C, 3 h) to furnish the optically active homoallylic alcohol **3** in 97% yield with an enantiomeric excess superior to 96%.<sup>3</sup> As the introduction and the stereocontrol of the second hydroxyl group was planned to require a 1,4-addition of a hemiacetal onto an unsaturated ester,<sup>4</sup> homoallylic alcohol **3** was transformed to the unsaturated ester **4** by using a cross-metathesis.<sup>5</sup> Thus, when **3** (1 equiv) was treated with ethyl acrylate (3 equiv) in the presence of the Grubbs–Hoveyda second generation catalyst HG-II<sup>6</sup> (5 mol%) ( $CH_2Cl_2$ , r.t., 2.5 d), the unsaturated ester **4** was isolated in 80% yield. Unsaturated ester **4** was then transformed to the protected 1,3-diol **5** in 68% yield with a *syn/anti* ratio of 98:2 after treatment with benzaldehyde under basic conditions (*t*-BuOK, THF, 0 °C, 2 h). At this stage, two additional steps were necessary to obtain the homologated unsaturated ester **8**, precursor of (+)-dodoneine. First, compound **5** was reduced to the corresponding aldehyde **6** (DIBAL-H, toluene, –78 °C, 1.5 h, 94% yield), and this latter compound was involved in a Horner–Wadsworth–Emmons reaction by using the Still–Gennari reagent **7**<sup>7</sup> (KHMDs, 18-C-6, THF, –78 °C, 2 h) to furnish the desired unsaturated ester **8** with a *Z/E* ratio of 90:10 and in 70% yield. In order to perform a three-step one-pot reaction to access (+)-dodoneine (deprotection of the phenol, deprotection of the diol and lactonization) compound





Figure 1

**8** was treated under acidic conditions. Thus, when **8** was treated with 80% aqueous AcOH, at 60 °C for 24 hours, (+)-dodoneine **9** was isolated in 70% yield (Scheme 2).<sup>8</sup> Gratifyingly, the <sup>1</sup>H and <sup>13</sup>C NMR spectra of **9** are in total agreement with those of the natural (+)-dodoneine. The HRMS and optical rotation confirmed that compound **9** is indeed (+)-dodoneine.



Scheme 2

In conclusion, the total synthesis of (+)-dodoneine has been accomplished in eight steps from commercially available ester **1** with an overall yield of 21.4%. The key bond-forming event involves an enantioselective allyltitanation, a 1,4-addition of a hemiacetal to an unsaturated ester, a cross-metathesis reaction, and a Still–Gennari-modified Horner–Wadsworth–Emmons reaction. The route detailed herein is flexible and can be used to synthesize isomers for SAR studies.

## Acknowledgment

We are indebted to Prof. J.-M. Coustard for providing us with the NMR spectra of natural (+)-dodoneine.

## References and Notes

- Ouedraogo, M.; Carreyre, H.; Vandebrouck, C.; Bescond, J.; Raymond, G.; Guissou, I.-P.; Cognard, C.; Becq, F.; Potreau, D.; Cousson, A.; Marrot, J.; Coustard, J.-M. *J. Nat. Prod.* **2007**, *70*, 2006.
- The allyltitanium complex (*S,S*)-Ti-I was prepared according to: Hafner, A.; Duthaler, R. O.; Marti, R.; Rihs, G.; Rothe-Streit, P.; Schwarzenbach, F. *J. Am. Chem. Soc.* **1992**, *114*, 2321.
- The ee of **3** and its *S* absolute configuration were determined by <sup>1</sup>H NMR after derivatization with (*S*)- and (*R*)-methoxyphenylacetic acids. See: (a) Dale, J. A.; Mosher, H. S. *J. Am. Chem. Soc.* **1973**, *95*, 512. (b) Trost, B. M.; Belletire, J. L.; Godleski, S.; McDougal, P. G.; Balkovec, J. M. *J. Org. Chem.* **1986**, *51*, 2370. (c) Seco, J. M.; Quiñoà, E.; Riguera, R. *Tetrahedron: Asymmetry* **2001**, *12*, 2915.
- Evans, D. A.; Gauchet-Prunet, J. A. *J. Org. Chem.* **1993**, *58*, 2446.
- Cossy, J.; Bouzbouz, S.; Hoveyda, A. H. *J. Organomet. Chem.* **2001**, *624*, 327.
- Kingsbury, J. S.; Harrity, J. P. A.; Bonitatebus, P. J. Jr.; Hoveyda, A. H. *J. Am. Chem. Soc.* **1999**, *121*, 791.
- Still, W. C.; Gennari, C. *Tetrahedron Lett.* **1983**, *24*, 4405.
- Compound **9**: *R*<sub>f</sub> = 0.23 (PE–EtOAc, 2:8); [*α*]<sub>D</sub><sup>20</sup> +48.1 (*c* = 0.34, CHCl<sub>3</sub>) {Lit.<sup>1</sup> [*α*]<sub>D</sub><sup>20</sup> +40.2 (*c* = 0.40, CHCl<sub>3</sub>)}. IR (neat): 3311, 2920, 1698, 1515 cm<sup>-1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ = 7.05 (app dt, *J* = 8.5, 2.5 Hz, 2 H), 6.88 (app dt, *J* = 9.5, 4.1 Hz, 1 H), 6.76 (app dt, *J* = 8.5, 2.5 Hz, 2 H), 6.02 (dt, *J* = 9.8, 1.9 Hz, 1 H), 5.32 (br s, 1 H), 4.65 (dddd, *J* = 7.7, 7.7, 5.3 Hz, 1 H), 3.87 (m, 1 H), 2.67 (m, 2 H), 2.38 (m, 2 H), 2.00 (dt, *J* = 15.7, 8.2 Hz, 1 H), 1.90 (br s, 1 H, OH), 1.79 (m, 3 H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ = 164.6 (s), 154.3 (s), 145.8 (d), 133.9 (s), 129.8 (2 × d), 121.5 (d), 115.7 (2 × d), 77.4 (d), 69.0 (d), 42.4 (t), 39.7 (t), 31.2 (t), 29.8 (t). MS (EI, 70 eV): *m/z* (%) = 262 (5), 150 (2), 133 (10), 120 (9), 108 (27), 107 (100), 94 (14), 77 (49), 67 (23), 53 (22). HRMS (ESI): *m/z* [M + Na]<sup>+</sup> calcd for C<sub>15</sub>H<sub>18</sub>O<sub>4</sub>Na: 285.10987; found: 285.10973.